MARKET

BSTG

BSTG

Biostage
OTCMQB

Real-time Quotes | Nasdaq Last Sale

5.13
+0.42
+8.92%
Opening 09:30 05/23 EDT
OPEN
--
PREV CLOSE
5.13
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
6.80
52 WEEK LOW
1.010
MARKET CAP
54.83M
P/E (TTM)
-15.6689
1D
5D
1M
3M
1Y
5Y
Insider Buy: Biostage
MT Newswires · 5h ago
Biostage reports Q1 results
Biostage press release (OTC:BSTG): Q1 GAAP EPS of -$0.20. As of March 31, 2022, the company had operating cash on-hand of $0.7 million. Expects that its current cash will be sufficient to fund
Seekingalpha · 05/16 20:17
Cell-therapy biotechnology company Biostage raises ~$5.1M to advance clinical trial
Cell-therapy biotechnology company, Biostage (OTC:BSTG) raises ~$5.1M from new and existing investors in a private placement of its shares.  The funds will be used to accelerate the clinical development of Biostage's
Seekingalpha · 05/13 14:00
Biostage Schedules Conference Call and Webcast for Q1 2022 Results
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence...
PR Newswire · 05/10 12:30
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a...
PR Newswire · 04/11 12:30
Biostage GAAP EPS of -$0.55
Biostage press release (OTC:BSTG): Q4 GAAP EPS of -$0.55. The company expects that operating cash on-hand as of December 31, 2021 of $1.2M will enable us to fund operating expenses
Seekingalpha · 04/01 11:43
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence...
PR Newswire · 03/30 18:49
Biostage rebounds after announcing court ruling against insurance carrier
Biostage (OTC:BSTG +6.1%) shares have made a comeback after announcing that a Court ordered its medical liability insurance carrier, Medmarc, breached its duty to defend the company in a lawsuit
Seekingalpha · 01/25 17:44
More
No Data
Learn about the latest financial forecast of BSTG. Analyze the recent business situations of Biostage through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-0.09-0.07-0.04-0.02
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 3
Institutional Holdings: 15.73K
% Owned: 0.15%
Shares Outstanding: 10.69M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.42%
Healthcare Equipment & Supplies
+0.73%
Key Executives
Chairman/Chief Executive Officer/Director
David Green
President
Hong Yu
Vice Chairman/Director
Jason Jing Chen
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
Peter Pellegrino
Chief Scientific Officer
Harout DerSimonian
Director
Ting Li
Director
Herman Sanchez
Director
James Shmerling
Independent Director
Junli He
Independent Director
Thomas Robinson
No Data
No Data
About BSTG
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

Webull offers kinds of Biostage Inc stock information, including OTCMQB:BSTG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BSTG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BSTG stock methods without spending real money on the virtual paper trading platform.